Resident Rotation: Collaborative Care Consultation Psychiatry

Similar documents
APPLYING THE INTEGRATED CARE APPROACH: PRACTICAL SKILLS FOR THE PSYCHIATRIC CONSULTANT WORKSHOP: ASSESSMENT AND TREATMENT IN COLLABORATIVE CARE

Antidepressant Medication Therapy in Primary Care July 25, 2013

Psychiatric Consultant Role in Collaborative Care Sept 12, 2013

Primary Care Provider & Psychiatric Consultant Roles. PC/PCP Role Session Objectives. Working as a Team. Joseph Cerimele Anna Ratzliff

Presentation is Being Recorded

Resident Rotation: Collaborative Care Consultation Psychiatry

9/20/2011. Integrated Care for Depression & Anxiety: Psychotropic Medication Management for PCPs. Presentation is Being Recorded

Depression Assessment and Management. John Kern MD Clinical Professor University of Washington

Quick Guide to Common Antidepressants-Adults

PRACTICAL MANAGEMENT OF DEPRESSION IN OLDER ADULTS. Lee A. Jennings, MD MSHS Assistant Professor Division of Geriatrics, UCLA

Principles in Action Case Example

Depression & Anxiety in Adolescents

Reducing the Anxiety of Pediatric Anxiety Part 2: Treatment

Children s Hospital Of Wisconsin

PRESCRIBING DIRECTIONS FOR PSYCHOTROPIC MEDICATIONS

Appendix 4B - Guidance for the use of Pharmacological Agents for the Treatment of Depression in Adults (18 years and over)

Psychiatry curbside: Answers to a primary care doctor s top mental health questions

Optimistic News and Practical Tools. The Role of Primary Care in Screening and Managing Teen Depression

Care Team Training. Key Components of Collaborative Care. Collaborative Team Approach 4/21/2014 PCP. Core Program. New Roles. Psychiatric Consultant

Overview. Part II: Part I: Screening for Depression and Anxiety Risk Assessment Diagnosis of Depressive Disorders

Mood Disorders for Care Coordinators

KEY MESSAGES. It is often under-recognised and 30-50% of MDD cases in primary care and medical settings are not detected.

ESCITALOPRAM. THERAPEUTICS Brands Lexapro see index for additional brand names. Generic? Yes

WILL LEXAPRO HELP DEPRESSION

Guidelines MANAGEMENT OF MAJOR DEPRESSIVE DISORDER (MDD)

Medication Guide. Sertraline Hydrochloride (ser' tra leen hye'' droe klor' ide) Tablets

Optimal Use of Antidepressants: Focusing on SNRI, NDRI and SSRE

MEDICATION ALGORITHM FOR ANXIETY DISORDERS

TOP APS DRUGS TRAZODONE BRAND NAMES: OLEPTRO, DESYREL (DIVIDOSE) & TRIALODINE

FLUVOXAMINE. THERAPEUTICS Brands Luvox, Luvox CR see index for additional brand names. Generic? Yes (not for fluvoxamine CR)

Medication Guide Sertraline Hydrochloride Tablets (ser-tra-leen HYE-droe-KLOR-ide)

Pharmaceutical Interventions. Collaborative Model of Mental Health Care for Older Iowans Des Moines May 18, 2007

Major Depressive Disorder (MDD) in Children under Age 6

Partners in Care Quick Reference Cards

Management Of Depression And Anxiety

Generalized Anxiety Disorder ( DSM -IV) is characterized by excessive anxiety and worry (apprehensive expectation) that is persistent for at least 6

Medication for Anxiety and Depression. PJ Cowen Department of Psychiatry, University of Oxford

Effective Date: 5/28/2014 Version: 2.0 (Revised: 10/12/2015) Approval By: CCC Clinical Delivery Steering Planned Review Date: (04/47/2017)

Wellbutrin/Wellbutrin-SR/ Wellbutrin-XL (bupropion)

Dementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist

Chronic Pain Care Management in Primary Care 12/16/2010. Jürgen Unützer, MD, MPH, MA UW Psychiatry and Behavioral Sciences

Major Depressive Disorder (MDD) in Children under Age 6

Antidepressant Selection in Primary Care

Zoloft (sertraline) FDA ALERT [05/2007] Suicidal Thoughts or Actions in Children and Adults

FROM MEDICATION TO MINDFULNESS: NEW INSIGHTS INTO THE WORLD OF ANXIETY

Celexa and sleeping pills

WHEN AND HOW TO USE BENZODIAZEPINES IN TREATING ANXIETY: AM I WITHHOLDING TREATMENT IF I DON'T USE BENZODIAZEPINES?

GREATER MANCHESTER INTERFACE PRESCRIBING GROUP

Depression Screening, Treatment and Follow-Up for Patients > Screening Treatment Follow-up References 4

Assessing and Treating Depression and Anxiety in Children with Cancer Anna (Nina) Muriel, MD, MPH

Treatment Algorithm Treatment Algorithm

ANXIETY: FAST FACTS AND SKILLS FOR THE PRIMARY CARE PHYSICIAN

5/12/11. Educational Objectives. Goals

2/23/18. Age of Anxiety: Transforming Qualms into Calm. Disclosures. Objectives. I have nothing to disclose

Practice Guideline for the Treatment of Patients With Major Depressive Disorder: American Psychiatric Association

Intro to Concurrent Disorders

5 COMMON QUESTIONS WHEN TREATING DEPRESSION

Diagnosis & Management of Major Depression: A Review of What s Old and New. Cerrone Cohen, MD

Venlafaxine hydrochloride extended-release and other antidepressant medicines may cause serious side effects, including:

SANDOMIGRAN (pizotifen malate)

Depression in adults: treatment and management

Realities of Depression in Primary Care Setting

Norpramin (desipramine)

10 INDEX Acknowledgements, i

6 semanas de embarazo. Celexa and sleeping pills. Inicio / Embarazo / 6 semanas de embarazo

Reduce hunger and help control cravings with CONTRAVE

VA/DoD Clinical Practice Guideline for Management of Post Traumatic Stress. Core Module

Guideline for the Diagnosis and Management of Generalized Anxiety Disorder for Primary Care Physicians

Treatment Options for Bipolar Disorder Contents

The legally binding text is the original French version TRANSPARENCY COMMITTEE. Opinion. 1 October 2008

Antidepressant Selection in Primary Care

in Primary Care Consultation Psychiatry Anna Ratzliff, MD, PhD Jürgen Unützer, MD, MPH, MA Learning Objectives: Module 3

COMMONLY PRESCRIBED PSYCHOTROPIC MEDICATIONS NAME Generic (Trade) DOSAGE KEY CLINICAL INFORMATION Antidepressant Medications*

ANTI-DEPRESSANT MEDICATIONS

Guidelines for the Utilization of Psychotropic Medications for Children in Foster Care. Illinois Department of Children and Family Services

Causes of Treatment Failure

Best Practices in Prescribing Benzodiazepines. Michael Carlisle, DO Medical Director University Hospitals Geauga Medical Center

Elavil (amitriptyline)

TIAGABINE. THERAPEUTICS Brands Gabitril see index for additional brand names. Generic? Yes

Treating Depression in Disadvantaged Women: What is the evidence?

VENLAFAXINE hydrochloride extended-release capsules, USP, for oral use Initial U.S. Approval: 1997

Depression Management

Daniel Suzuki, MD Adjunct Clinical Associate Professor of Psychiatry, USC Keck School of Medicine Clinical Adjunct Professor/Faculty, Graduate School

MEDICATION GUIDE. desvenlafaxine extended-release tablets (des VEN la FAX een)

Psychiatry in Primary Care: What is the Role of Pharmacist?

Schedule FDA & literature based indications

How to Manage Anxiety

Depression: selective serotonin reuptake inhibitors

Cravings are one of the main reasons diets fail

Index. Note: Page numbers of article titles are in boldface type. A ADHD. See Attention-deficit/hyperactivity disorder (ADHD) b-adrenergic blockers

Common Antidepressant Medications for Adults

MEDICATION GUIDE Savella (Sa-vel-la) (milnacipran HCl) Tablets

Obsessive-Compulsive Disorder Clinical Practice Guideline Summary for Primary Care

Medication Guide. Sertraline Hydrochloride Tablets USP. (ser tra leen)

Depression & Suicide 7/11/2017 DISCLOSURES. DSM 5 Depressive Disorders. Objectives

Depression: Identification, Evaluation and Management in Primary Care

(levomilnacipran) extended-release capsules

Appendix C: Algorithms. Algorithm C-1: Enhanced Screening Algorithm

3. Severe allergic reactions: trouble breathing swelling of the face, tongue, eyes or mouth

Depression and Anxiety. What is Depression? What is Depression? By Christopher Okiishi, MD Spring Not just being sad A syndrome of symptoms

Transcription:

Resident Rotation: Collaborative Care Consultation Psychiatry Anna Ratzliff, MD, PhD Ramanpreet Toor, MD James Basinski, MD With contributions from: Jürgen Unützer, MD, MPH, MA Jennifer Sexton, MD, Catherine Howe, MD, PhD Deborah Cowley, MD

Module 5: Collaborative Care Consultation: Making Recommendations and Treating to Target

Learning Objectives: Module 5 By the end of this module, the participant will be able to: Make treatment recommendations for common primary care presentations. Assess a patient that has not responded to initial treatment plan. Apply a stepped care approach to determine appropriate level of care.

Principles of Collaborative Care Population Based Care Measurement Based Treatment to Target Patient Centered Collaboration Evidence Based Care Accountable Care University of Washington

Principle: Measurement Based Treatment To Target 25 20 PHQ 9 Scores 15 10 5 Patient Blue Patient Red 0 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Weeks in Treatment ( 0 = Clinical Assessment) University of Washington

Caseload Summary: Prioritizing Cases to Review

Principal: Evidence Based Care

STAR D Summary Level 1: Citalopram ~30% in remission Level 2: Switch or Augmentation ~50% in remission Level 3: Switch or Augmentation ~60% in remission Level 4: Stop meds and start new ~70% in remission Rush, 2007

Treatment Options Bio Evidence based Medications Social Psycho Evidence based Psychotherapy Social support Make BOTH medication and non medication recommendations Supporting whole person treatment is important The treatment that WORKS is the best one Review all evidence based treatment options available Discuss pros and cons of each option

Recommendations: Medication Treatment Focus on evidencebased treatments and treatment algorithms Details about titrating and monitoring Brief medication instructions

Example: Prescribing Cheat Sheet Includes information such as: Basic education Names and doses of medication Common side effects Precautions University of Washington

Example: Sertraline (Zoloft) DOSING INFORMATION: Week 1: Baseline weight. Consider BMP for baseline sodium in older adults. Start: 25 mg qday. Week 2: Increase to an Initial Target Dose of 50 mg qday, if tolerated. Week 4 and beyond: Consider further increases in dose if needed and tolerated, in 25 mg qday per week increments. Typical Dosage Range: 50 200 mg qday. Max Dose: 200 mg qday. Discontinuation: 25% per week to 25% per month depending on length of treatment in order to minimize withdrawal symptoms and relapse. Monitoring: Weight. Consider posttreatment BMP to rule out hyponatremia in older adults. OF NOTE: false positive urine immunoassay screening tests for benzodiazepines have been reported in patients taking sertraline. General Information: Mechanism of Action: Selective serotonin reuptake inhibitor. FDA Indications: MDD, OCD, panic disorder, PTSD, social phobia, PMDD. Off Label Indications: Other anxiety. Pharmacokinetics: T½ = 26 hrs. Common Side effects (MDD): Nausea (26%), diarrhea (18%), dry mouth (16%), insomnia (16%), somnolence (13%), dizziness (12%), tremor (11%), fatigue (11%), increased sweating, (8%), ejaculation failure (7%). Black Box Warning: Increased SI in patients < 25 y/o. Contraindications: Known hypersensitivity reaction to Zoloft. Use of a MAOI within 4 weeks of stopping Zoloft, concurrent use of a MAOI including drugs with significant MAOI activity (e.g., linezolid), or use of Zoloft within 4 weeks of stopping a MAOI. Concomitant use with pimozide. Warnings and Precautions: Clinical worsening and suicide risk, hypomanic/manic switch, serotonin symptoms, weight loss, seizure, discontinuation symptoms, abnormal bleeding, altered platelet function, hyponatremia, weak uricosuric effect, angle closure glaucoma. Metabolism/Pharmacogenomics: Metabolized by multiple P450 enzymes with 2C19 having the greatest pharmacogenetic and drug drug interaction evidence. Use caution with 2C19 poor metabolizers. Significant drug drug interactions: Weak 2D6 inhibitor. Use caution with drugs metabolized by 2D6 (e.g., TCAs); check all drug drug interactions. Pregnancy: Category C. Breastfeeding: Compatible. Dosage Form: Oral solution, Tablet. Generic available: Yes. University of Washington Cost:. FDA label information from Drugs @FDA for Zoloft dated 2.1.2013.

Making Effective Recommendations: Sample Case Review Note SUMMARY: Pt is a 28yo male presenting with depression and anxiety. He has had an acute stressor related to job loss and relationship difficulties. Pt having trouble falling asleep (plays with laptop or phone in bed), sleeping 4 7 hrs/night. Depressive symptoms: Moderate depression; PHQ 9: 18 Bipolar Screen: Positive screen; Appears more consistent with substance use Anxiety symptoms: Moderate to severe; GAD 7: 18 Past Treatment: Currently taking Bupropion and Citalopram (since 1/31) feels more in control, able to think before reacting, less irritable; Took sertraline, fluoxetine, bupropion at different times during teenage yrs: Doesn't recall effect Suicidality: Denies Psychotic symptoms: Denies Substance use: History of substance use/alcohol; Engaged in treatment currently Psychosocial factors: Completed court appointed time in clean and sober housing; Now living back with parents in Carnation; Attending community college; Continues to stay connected to clean and sober housing Other: ADHD: ASRS v1.1 screening positive; Not diagnosed as a child; Now getting B s at community college Medical Problems: hx of frequent migraines Current medications: Bupropion HCl (Daily Dose: 450mg); Citalopram Hydrobromide (Daily Dose: 40mg) Goals: Improve school functioning; Long term goal employment

ASSESSMENT: MDD (but cannot r/o bipolar disorder); Anxiety NOS; Alcohol use disorder, in early remission; r/o ADHD RECOMMENDATIONS: 1) Continue to target sleep hygiene 2) Options for antidepressant augmentation. Engage patient in decision making about which ONE option to pursue: a. Option 1: Continue citalopram to 20mg as reported sedation on higher dose; Make sure he is taking dose at night and allow for longer period of observation to evaluate efficacy b. Option 2: Cross taper to fluoxetine; Week 1: Baseline weight. Consider BMP for baseline sodium in older adults. Start fluoxetine 10 mg qday. Continue citalopram 20mg Week 2: Increase dose of fluoxetine to 20 mg qday, if tolerated, and stop citalopram Week 4 and beyond: Consider further titration of fluoxetine in 10 20 mg qday increments. Typically need higher doses for anxiety Typical target dosage: 20 mg qday 3) Continue close contact with care coordinator, supporting substance use treatment and behavioral activation. 4) Can consider straterra in the future if poor concentration persists; Would stay on 40 mg qday as combination with bupropion can increase drug level.

Caseload Consultation If patients do not improve, consider: Wrong diagnosis? Problems with treatment adherence? Insufficient dose / duration of treatment? Side effects? Other complicating factors? psychosocial stressors / barriers medical problems / medications psychological barriers substance abuse other psychiatric problems Initial treatment not effective?

A Different Kind of Treatment: Care Shaped Over Time Traditional Consult One Session = One Time Recommendation Collaborative Care Jan: Review 1 MDD and initiate treatment Engaged with team but still symptomatic Feb: Review 2 Adjust treatment Engaged with team but persistent symptoms Mar: Review 3 intensify treatment

Typical Course of Care Management: Contact Frequency Active Treatment Until patient has >50% decrease in symptoms and/or PHQ 9 score under 10 Minimum 2 contacts per month Typical during first 3 6 months of treatment Mix of phone and in person works Monitoring 1 contact per month After 50% decrease in PHQ / GAD (or similar) achieved Monitor for ~3 months to ensure patient stable

Typical Course of Care Management: Duration Primary Care Panel Collaborative Care Caseload University of Washington Referral to Specialty Mental Health Relapse Prevention

Comparison of Contacts in Usual Care vs. IMPACT Collaborative Care = PCP contact (avg. 3.5 contacts per year) = Contacts with BHP/CM (avg. 10 contacts) = Case reviews from psychiatric consultant to BHP/CM, PCP (avg. 2 case reviews) 0 50% 70% treatment response/improvement 12 months

Recommendations: Other Interventions Support managing difficult patients Working with demanding patients Protocols for managing suicidal ideation Working with patients with chronic pain More recommendations Beyond Medications Behavioral Medicine and Brief Psychotherapy Referrals and Community Resources Disability

Recommendations: Example Working with Difficult Patients Coaching PCP Skills: How to say no to a demanding patient. Set your goals Recognize your own values and triggers Consider using a preplanned strategy for situations that you encounter often, i.e. narcotics/unnecessary tests Explore patient s goals/concerns How had you hoped I could help you with this? Try to find underlying concerns This may change a rant into a conversation Try Disarming Statements Actively helps pt make their point and calm down I see your point, I understand, I agree You re right, you did have to wait a long time Model calmness. Lower your voice, move so they must turn in your direction Encourage them to sit down but let them control where to sit

Supporting Care Team Members Work with Difficult Patients Drawing upon psychotherapeutic understandings of patients to support the care team. Some examples: Observing interpersonal limits and boundaries in externalizing patients with dialectical balance between empathizing and understanding rationales for dysfunctional behaviors while promoting more adaptive ones Recognizing patients difficulties trusting others and accepting help, or in contrast overvaluing self assertiveness and being independent coaching care managers to recognize their characteristic responses to such interpersonal styles Validating the importance and frequent difficulty of tolerating and responding empathically to negative emotions in patients Helping set realistic expectations for patient outcomes for patients with complex and chronic problems; Shifting focus to appreciating the progress however small patients do make

Reflection Questions 1) What experiences have you had making recommendations on consultation services? How is this similar and different to treating patients directly? 2) How do you keep current about evidence based treatments? How do you plan to do this in your career? 3) What are your experiences with brief behavioral interventions? What do you think will be challenging and rewarding in coaching care mangers about these types of treatments?